Le Lézard
Classified in: Covid-19 virus
Subject: Nonprofit

Susan G. Komen® Urges Women to Continue to Get Mammograms


Susan G. Komen®, the world's leading breast cancer organization, urged women to not unduly delay their regularly scheduled breast cancer screening and to speak with a doctor immediately if she, or he, is displaying any signs of breast cancer. The renewed call came following new recommendations from the Society of Breast Imaging (SBI), which states that women who receive a COVID-19 vaccine may experience swollen lymph nodes that may impact the results of a mammogram and should therefore either schedule mammograms before or delay mammograms for at least four weeks following their shot.

Lymph node swelling in the armpit near the shot location is a side effect of some vaccines, including COVID-19 vaccines, and is likely an indicator that the immune system is responding to the vaccine. However, women who experience this post-vaccine side effect may worry that they have developed breast cancer, and the swollen lymph nodes may display on a mammogram. Komen noted that some women may experience this swelling, but it is unclear at this point how prevalent it is.

The Society of Breast Imaging issued these recommendations to ensure that radiologists who read mammograms are aware that such swelling may occur in patients who were recently vaccinated. Among other recommendations, SBI suggested that mammography providers ask patients about their COVID-19 vaccination status and consider scheduling screening exams prior to receiving the first dose of the vaccine or 4-6 weeks after the second dose.

"We are deeply concerned about the reduction in breast cancer screening we have already seen in women concerned about COVID-19 exposure, and potentially a surge in later stage diagnoses and worse outcomes, as a result," said Victoria Wolodzko, Komen's senior vice president of mission. "It is important to note that the SBI recommendations are not based on doctors seeing a significant increase in women with confusing symptoms. Rather, SBI was issuing guidance to inform women and radiologists of the possibility and provide them with recommendations to improve the care being given to women at this time."

Wolodzko added, "As such, women should not preemptively delay their screening just because they have been vaccinated, unless it is convenient, and a new time can be secured. A recent vaccination is important information, but not necessarily a cause for delay. And women should contact their doctors particularly if they are displaying any warning signs of breast cancer."

Komen noted that knowledge is power. Women should have conversations with their health care provider about when screening is right for them and let their providers know about recent vaccinations. Not all women will experience this side effect of COVID vaccines, but all women are at risk of breast cancer.

About Susan G. Komen®

Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social media.


These press releases may also interest you

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:09
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...

at 08:05
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:00
The "Global Men's Health and Wellness Market: Analysis By Type, By Distribution Channel, By Region Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's offering. In 2023, the...

at 08:00
Citius Pharmaceuticals Inc. ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that it has entered into definitive...



News published on and distributed by: